Keros Therapeutics: A Biotech Stock on the Move Amid Strategic Review and Rights Plan
In a move that’s got investors buzzing, Keros Therapeutics (NASDAQ: KROS) has announced a review of strategic alternatives to maximize stockholder value. This news comes as of this writing, the company’s shares have surged 14.42% today, making it one of the biggest gainers in the market. As we take a closer look at this biotech … Read more